KEY TAKEAWAYS
- The STRIDE trial aimed to identify pts who benefited the most from the STRIDE intervention by examining the characteristics that may have affected how well the intervention worked for them.
- The study used hierarchical linear modeling to test which patient characteristics moderated the effects of the STRIDE intervention on adherence rates, controlling for ovarian suppression receipt and baseline distress.
- The study showed that patient-level and socioeconomic factors can influence response to AET adherence interventions.
Breast cancer(BC) patients(pts) taking adjuvant endocrine therapy (AET) have a lower risk of cancer returning, but many pts don’t take it as prescribed. Clinicians should help BC pts adhere to their AET regimen.
Researchers aimed to identify patients who benefited the most from the STRIDE intervention by examining the characteristics that may have affected how well the intervention worked for them.
The study randomly assigned women (n = 100) with nonmetastatic BC who reported AET-related distress to either the STRIDE intervention or a medication monitoring control (MM) group between October 2019 and June 2021. They involved six weekly small-group cognitive behavioral telehealth sessions to enhance symptom management and adherence. Patient characteristics (i.e., months on AET, education) were collected, along with self-report measures, at the start of the study. Pts used the Medication Adherence Report Scale (MARS-5) and Cancer Therapy Satisfaction Questionnaire to report on adherence behaviors (e.g., “I alter the dose”) and their perceptions of anti-estrogen therapy (AET) (e.g., convenience, expectations, satisfaction). They employed hierarchical linear modeling to examine factors that influenced the impact of the intervention on adherence rates measured with (MEMS Caps) during months 1 to 3. This analysis considered variations in ovarian suppression receipt and baseline distress attributed to group differences and stratification. Results related to the interaction of ‘time X group X moderator was presented.
Pts who initially found their AET regimen more challenging (lower MARS-5 scores), pts exhibited more significant improvements in adherence over time compared to MM pts (b = -13.80, SE = 4.56, P< .01). Greater expectations of therapeutic benefits were linked to adherence improvements in STRIDE versus MM participants (b = 0.25, SE = 0.10, P= .01). Among pts who reported finding AET more convenient (b = 0.33, SE = 0.17, P= .06), had lower education levels (b = -4.02, SE = 2.12, P= .06), and had been taking AET for a shorter duration (b = -0.43, SE = 0.25, P= .09), pts showed nearly significant increases in adherence. Other moderators did not yield significant results.
The study showed that patient-level and socioeconomic factors can influence response to AET adherence interventions.
Source: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.12131
Clinical Trial: https://www.clinicaltrials.gov/study/NCT03837496
Jamie M. Jacobs, Emily A Walsh, Nora K. Horick, Kathryn Elizabeth Post, Michael Antoni, Steven A. Safren, Ann H. Partridge, Jeffrey M. Peppercorn, Elyse R Park, Jennifer S. Temel, and Joseph A. Greer. DOI: 10.1200/JCO.2023.41.16_suppl.12131 Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) 12131-12131.
